Back

Plasma levels measurement of the four direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Unmet needs in anticoagulant pharmacotherapy Anticoagulants ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Riccardo Mazza

IRCCS San Raffaele Scientific Institute, Milan (Italy)

7 More presentations in this session

Presentation thumbnail
Clinical impact of kidney function in patients with atrial fibrillation receiving oral anticoagulants
Doctor Y. Matsuoka (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Navigating optimal antithrombotic therapy in atrial fibrillation patients with PCI: insights from the EPIC-CAD trial
Doctor S. Wee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of direct oral anticoagulants for treatment of left ventricular thrombus
Doctor K. Abraham (Stony Brook, US)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants versus warfarin for left ventricular thrombus
Doctor J. Kassab (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Pharmacokinetics and pharmacodynamics of SHR-2004, a novel humanized monoclonal antibody targeting factor XI, in patients with atrial fibrillation
Professor J. Jiang (Hangzhou, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Unmet needs in anticoagulant pharmacotherapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death
thumbnail
Congress Presentation
Plasma apixaban levels and thrombin generation assay in patients with atrial fibrillation with dose reduction criteria of apixaban
thumbnail
Congress Presentation
Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: an analysis from 4-year data of the ETNA-AF Europe programme

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources